EndocardialVascularEndothelialGrowth Factor D(VEGF-D)Gene Therapy for the Treatment of Severe Coronary Heart Disease

Phase 1 Completed 30 enrolled Kuopio University Hospital University of Eastern Finland · collab

RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of the study is to evaluate the safety and efficacy of catheter mediated endocardial adenovirus VEGF-D gene therapy in patients with severe coronary heart disease.

Timeline

Start: 2010-01-10
Primary completion: 2015-06-15
Completion: 2015-06-15

Publications

Leikas AJ, Hassinen I, Kivela A, Hedman A, Mussalo H, Yla-Herttuala S, Hartikainen JEK. Intramyocardial adenoviral vascular endothelial growth factor-D∆N∆C gene therapy does not induce ventricular arrhythmias. J Gene Med. 2022 Aug;24(8):e3437. doi: 10.1002/jgm.3437. Epub 2022 Jul 6.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AdVEGF-D	Unknown	1e+09 unknown	Other
Subject	AdVEGF-D	Unknown	1e+10 unknown	Other
Subject	AdVEGF-D	Unknown	1e+11 unknown	Other

EndocardialVascularEndothelialGrowth Factor D(VEGF-D)Gene Therapy for the Treatment of Severe Coronary Heart Disease

Summary

Timeline

Publications

Drugs

Indications